3 New Opportunities Canadian Cannabis Updates Investors Should Know About Before Trading

It is important for investors to stay on top of this market in order to make smart buying and trading decisions and jumping on new opportunities.  Here are 3 new developments you should be aware of:

Cronos: On September 1, Cronos announced that one of its wholly-owned licensed producers, Peace Naturals Project entered a supply agreement with Germany-based Cannamedical Pharma GmbH, a pharmaceutical and narcotics wholesaler that is federally licensed for narcotics import. Next month, Cannamedical expects Peace to export one of the single largest shipments of medical cannabis in the European Union’s history which will help with the ongoing medical cannabis shortage in Germany.

Organigram: Organigram Holdings (OGI.V)(OGRMF) first quarter financial results indicate their shares have been trending lower and growing weaker.  However, last week, Organigram reported an expansion of its cannabis oil product line with the introduction of a pure CBD edible oil called Shubie, selling at $129 CDN for registered patients so only time will tell if their shares will pick back up again over the next year.

Marapharm: The agreement Marapharm Ventures Inc. (MDM.CN) (MRPHF) made with Standard Graphite Corporation (SGH.V) in June 2017, to sell its ACMPR medical cannabis license application, and all associated property, plans, and intellectual property for approx. $8 million, has been called off. Their new plan is to pursue ACMPR grower status to maximize the value for their shareholders.  Overall, the market’s attraction to Marapharm has grown weaker and shares have fallen approx. 30% since July.

 

Read more here for details